OpportunityTitle: Alzheimer&apos;s Disease Phase I Clinical Trials (R01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:   Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.    Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: The objective of the Alzheimer&apos;s Disease Phase I Clinical Trials initiative is to provide support for first-in-human studies for promising Alzheimers disease therapeutics. These first stage clinical trials will evaluate the metabolic and pharmacological actions of drugs, including biologics in humans.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster &lt;br/&gt;FBOWebmaster@OD.NIH.GOV &lt;br/&gt;